Protein Kinase Inhibitors: all 15,278 studies that test it

Page 38 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationCompletedNCT03253679Phase 2Results posted
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCompletedNCT03252587Phase 2Results posted
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1Results posted
• Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerCompletedNCT03246074Phase 1Results posted
• Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsCompletedNCT03245151Phase 1/2Results posted
• A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompletedNCT03239340Phase 2Results posted
• A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedNCT03238651Phase 1Results posted
• Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results posted
• A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorCompletedNCT03235544Phase 2Results posted
• Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisCompletedNCT03233230Phase 2Results posted
• Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerTerminatedNCT03232892Phase 2Results posted
• Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasCompletedNCT03231306Phase 2Results posted
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCompletedNCT03230318Phase 2Results posted
• A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedNCT03225716Phase 1Results posted
• M3541 in Combination With Radiotherapy in Solid TumorsTerminatedNCT03225105Phase 1Results posted
• Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingNCT03224767Phase 2Results posted
• Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.CompletedNCT03224104Phase 1Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasActive, not recruitingNCT03220022Phase 1Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal CancerCompletedNCT03215264Phase 1Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213691Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaTerminatedNCT03213626Phase 2Results posted
• A Study of Baricitinib in Healthy ParticipantsCompletedNCT03212638Phase 1Results posted
• Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver CancerCompletedNCT03211416Phase 1/2Results posted
• A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque PsoriasisCompletedNCT03210961Phase 1Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTerminatedNCT03207815Phase 2Results posted
• Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)CompletedNCT03207555Phase 2Results posted
• Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
• Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
• Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCompletedNCT03206177Phase 1Results posted
• Nilotinib in Parkinson's DiseaseCompletedNCT03205488Phase 2Results posted
• A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedNCT03205046Phase 1/2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedNCT03203642Phase 2Results posted
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2Results posted
• Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaTerminatedNCT03201250Phase 1/2Results posted
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentCompletedNCT03200717Phase 2Results posted
• Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasActive, not recruitingNCT03198026Phase 2Results posted
• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedNCT03194893Phase 3Results posted
• Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03194373Phase 2Results posted
• TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast CancerCompletedNCT03193853Phase 2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedNCT03193190Phase 1/2Results posted
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaActive, not recruitingNCT03190915Phase 2Results posted
• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4Results posted
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersCompletedNCT03190174Phase 1/2Results posted
• Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy SubjectsCompletedNCT03189589Phase 1Results posted
• A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03184571Phase 2Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedNCT03184558Phase 2Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedNCT03182244Phase 3Results posted
• A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing SpondylitisCompletedNCT03178487Phase 2Results posted
• TGR1202 in Relapsed and Refractory Follicular LymphomaTerminatedNCT03178201Phase 2Results posted
• A Study of ONO-7475 in Patients With Acute LeukemiasTerminatedNCT03176277Phase 1/2Results posted
• Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT03176238Phase 3Results posted
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
• Study of Copanlisib in Hepatic or Renal ImpairmentCompletedNCT03172884Phase 1Results posted
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
• Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingNCT03155997Phase 3Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsCompletedNCT03154294Phase 1Results posted
• Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastCompletedNCT03154281Phase 1Results posted
• Ruxolitinib in Operable Head and Neck CancerTerminatedNCT03153982Phase 2Results posted
• Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedNCT03151057Phase 1Results posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• Inhibition of Anaphylaxis by IbrutinibCompletedNCT03149315Phase 2Results posted
• Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by SurgeryCompletedNCT03148275Phase 2Results posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome PatientsTerminatedNCT03145480Phase 2Results posted
• Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)CompletedNCT03144674Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT03142191Phase 2Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedNCT03139604Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataCompletedNCT03137381Phase 2Results posted
• A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).CompletedNCT03137069Phase 2Results posted
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)CompletedNCT03134222Phase 2Results posted
• 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedNCT03133221Phase 2Results posted
• QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell SarcomaTerminatedNCT03132155Phase 2Results posted
• LAM Pilot Study With Imatinib MesylateCompletedNCT03131999Phase 1/2Results posted
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerTerminatedNCT03131206Phase 1/2Results posted
• Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerTerminatedNCT03130439Phase 2Results posted
• Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT03128411Phase 2Results posted
• A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaCompletedNCT03126019Phase 2Results posted
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03123393Phase 2Results posted
• Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationTerminatedNCT03121534Phase 2Results posted
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedNCT03112603Phase 3Results posted
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingCompletedNCT03109015Phase 2Results posted
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 2Results posted
• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)CompletedNCT03107988Phase 1Results posted
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedNCT03106779Phase 3Results posted
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT03106415Phase 1/2Results posted

← Protein Kinase Inhibitors overview